Long-acting antiretrovirals: a new era for the management and prevention of HIV infection

The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA, EMA and Health Canada approval. This novel drug delivery approach is about to revolutionize the therapy of people living with HIV, decreasing the 365 daily pill burden to only six intramuscular injections...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoueille, Paul, Choong, Eva, Cavassini, Matthias, Buclin, Thierry, Decosterd, Laurent A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809192/
https://www.ncbi.nlm.nih.gov/pubmed/34499731
http://dx.doi.org/10.1093/jac/dkab324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809192/
https://www.ncbi.nlm.nih.gov/pubmed/34499731
http://dx.doi.org/10.1093/jac/dkab324

Ejemplares similares